CAS 89778-27-8 Toremifene Citrate Raw Powder For Breast Cancer

Description

Fareston will exhibit both antagonist/agonist properties in vivo. That puts Fareston in the same class as Nolvadex and Clomid, two of the most popular drugs in the Fareston category. FARESTON is an agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with receptor-positive or unknown tumors.

Three months of toremifene administration in men with idiopathic oligospermia was associated with significant improvements in sperm count, motility, and morphology mediated by increased gonadotropin secretion, likely a direct beneficial effect of toremifene on the testes . The above findings also suggest that men whose partners have successfully conceived have a better exocrine (improved sperm parameter) response to treatment than men whose partners have not conceived. Further randomized, placebo-controlled trials should be conducted to determine whether this specific selective receptor modulator can be used as an initial treatment for oligospermia in men.

This product is a tamoxifen derivative. It can combine with receptors to produce -like effects, anti-hormone effects or both effects, which mainly depends on the length of treatment, animal species, sex and target organs. In general, non-steroidal triphenylethylene derivatives exhibit mainly  effects in humans and rats, and -like effects in mice.

The application of toremifene citrate in postmenopausal breast cancer patients led to a moderate decrease in serum total cholesterol and low-density lipoprotein (LDL).

Toremifene citrate competes with to bind to receptors in breast cancer cells, preventing -induced DNA synthesis and proliferation of cancer cells. High-dose toremifene citrate was used in some experimental tumors, showing that toremifene citrate has non-dependent antitumor effects. The anti-breast cancer effect of toremifene citrate is mainly , and may also have other anti-cancer mechanisms (altering tumor gene expression, secreting growth factors, inducing apoptosis and affecting cell kinetic cycle).

Application

receptor-positive or unspecified metastatic breast cancer in postmenopausal women.